Efficacy of topical moxifloxacin on therapeutic laparoscopy-induced wound healing: a double-blind, randomized clinical trial.

IF 1.8 3区医学 Q2 SURGERY

BMC Surgery Pub Date : 2025-05-06 DOI:10.1186/s12893-025-02932-7

Behrooz Heydari, Ali Basiratian, Farahnaz Hoseinzade, Saeed Kargar, Vahid Ramezani, Amirhossein Zahmatkesh, Fatemeh Saghafi

{"title":"Efficacy of topical moxifloxacin on therapeutic laparoscopy-induced wound healing: a double-blind, randomized clinical trial.","authors":"Behrooz Heydari, Ali Basiratian, Farahnaz Hoseinzade, Saeed Kargar, Vahid Ramezani, Amirhossein Zahmatkesh, Fatemeh Saghafi","doi":"10.1186/s12893-025-02932-7","DOIUrl":null,"url":null,"abstract":"Background: Wound healing is crucial for maintaining healthy skin and preventing complications. Topical administration is a preferred method for delivering therapeutic medicines at the surgery site, as it is simple, affordable, and does not result in systemic harm or antibiotic resistance. Moxifloxacin (MXF), a broad-spectrum antibiotic with anti-inflammatory effects, seems to be effective against bacteria and accelerates wound healing. This study aims to determine the therapeutic effect of topical MXF on wound healing after therapeutic laparoscopy.Methods: This double-blind clinical trial involved 80 patients with therapeutic laparoscopy-induced wounds, randomly assigned to either 0.5% MXF cream or placebo, 24 h after surgery. The primary outcome was wound healing assessment using the REEDA index. Patients were followed by 1, 3, and 5 days of inclusion.Results: Of the 80 study participants included, 50 were women (62.5%), with the mean (SD) age of the participants being 49.5 (19.8) years in the MXF group and 45.8 (17.8) years in the control group. The severity of redness, oedema, and discharge in the MXF group was significantly lower on the first, third, and fifth days of treatment. The case group showed a significant decrease in ecchymosis from the third day of treatment compared to the control group, and no significant difference was observed in wound approximation rate. Hence, topical MXF therapy yielded a significant decrease in REEDA index MXF (P-Value < 0.0001). No treatment-related serious adverse events occurred in the MXF group vs. the comparator group.Conclusions: The results of the current clinical trial demonstrated that the use of topical MXF could be a potential option to expedite therapeutic laparoscopy-induced wound healing by reducing redness, oedema, ecchymosis, and discharge with a satisfactory safety profile.Trial registration: IRCT20181208041882N5, 25/10/2021 ( https://en.irct.ir/trial/46768 ).","PeriodicalId":49229,"journal":{"name":"BMC Surgery","volume":"25 1","pages":"198"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054187/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12893-025-02932-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Wound healing is crucial for maintaining healthy skin and preventing complications. Topical administration is a preferred method for delivering therapeutic medicines at the surgery site, as it is simple, affordable, and does not result in systemic harm or antibiotic resistance. Moxifloxacin (MXF), a broad-spectrum antibiotic with anti-inflammatory effects, seems to be effective against bacteria and accelerates wound healing. This study aims to determine the therapeutic effect of topical MXF on wound healing after therapeutic laparoscopy.

Methods: This double-blind clinical trial involved 80 patients with therapeutic laparoscopy-induced wounds, randomly assigned to either 0.5% MXF cream or placebo, 24 h after surgery. The primary outcome was wound healing assessment using the REEDA index. Patients were followed by 1, 3, and 5 days of inclusion.

Results: Of the 80 study participants included, 50 were women (62.5%), with the mean (SD) age of the participants being 49.5 (19.8) years in the MXF group and 45.8 (17.8) years in the control group. The severity of redness, oedema, and discharge in the MXF group was significantly lower on the first, third, and fifth days of treatment. The case group showed a significant decrease in ecchymosis from the third day of treatment compared to the control group, and no significant difference was observed in wound approximation rate. Hence, topical MXF therapy yielded a significant decrease in REEDA index MXF (P-Value < 0.0001). No treatment-related serious adverse events occurred in the MXF group vs. the comparator group.

Conclusions: The results of the current clinical trial demonstrated that the use of topical MXF could be a potential option to expedite therapeutic laparoscopy-induced wound healing by reducing redness, oedema, ecchymosis, and discharge with a satisfactory safety profile.

Trial registration: IRCT20181208041882N5, 25/10/2021 ( https://en.irct.ir/trial/46768 ).

查看原文本刊更多论文

外用莫西沙星治疗腹腔镜伤口愈合的疗效：一项双盲、随机临床试验。

背景：伤口愈合是维持皮肤健康和预防并发症的关键。局部给药是在手术部位提供治疗药物的首选方法，因为它简单，负担得起，并且不会导致全身伤害或抗生素耐药性。莫西沙星（MXF）是一种具有抗炎作用的广谱抗生素，似乎对细菌有效，并加速伤口愈合。本研究旨在探讨外用MXF对治疗性腹腔镜术后创面愈合的影响。方法：本双盲临床试验纳入80例腹腔镜治疗性伤口患者，术后24小时随机分配0.5% MXF乳膏或安慰剂。主要终点是使用REEDA指数评估伤口愈合。患者随访1、3、5天。结果：纳入的80名研究参与者中，女性50人（62.5%），MXF组参与者的平均（SD）年龄为49.5（19.8）岁，对照组参与者的平均（SD）年龄为45.8（17.8）岁。在治疗的第1天、第3天和第5天，MXF组的红肿、水肿和分泌物的严重程度显著降低。与对照组相比，病例组从治疗第3天起瘀斑明显减少，伤口近似率无显著差异。因此，局部MXF治疗可显著降低REEDA指数MXF （p值）。结论：目前的临床试验结果表明，局部使用MXF可能是一种潜在的选择，可以通过减少红肿、水肿、瘀斑和分泌物来加速腹腔镜诱导的伤口愈合，并具有令人满意的安全性。试验注册：IRCT20181208041882N5, 25/10/2021 （https://en.irct.ir/trial/46768）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊